HIV molecular immunology database

 

Search Antibody Database

Found 2 matching records:

Displaying record number 477

Download this epitope record as JSON.

MAb ID SP.BAL114
HXB2 Location gp160(308-317)
DNA(7146..7175)
gp160 Epitope Map
Author Location gp120( BAL)
Epitope SIHIGPGRAF Epitope Alignment
SIHIGPGRAF epitope logo
Ab Type gp120 V3 // V3 glycan (V3g)
Neutralizing L
Species (Isotype) mouse(IgG2aκ)
Patient  
Immunogen  
Keywords  

Notes

Showing 2 of 2 notes.

References

Showing 2 of 2 references.

Arendrup1995 M. Arendrup, L. Akerblom, P. M. Heegaard, J. O. Nielsen, and J. E. Hansen. The HIV-1 V3 domain on field isolates: participation in generation of escape virus in vivo and accessibility to neutralizing antibodies. Arch. Virol., 140:655-670, 1995. The anti-V3 Ab titre in patient serum was generally low against autologous virus isolated later than the serum sample, in contrast to a higher titre against peptides corresponding to virus isolated earlier than the serum sample. The authors conclude that the V3 domain is subject to immunoselection in vivo, and that V3 on early field virus is less accessible to NAbs than the V3 loop on laboratory strains. PubMed ID: 7794110. Show all entries for this paper.

Kanduc2008 Darja Kanduc, Rosario Serpico, Alberta Lucchese, and Yehuda Shoenfeld. Correlating Low-Similarity Peptide Sequences and HIV B-Cell Epitopes. Autoimmun. Rev., 7(4):291-296, Feb 2008. PubMed ID: 18295732. Show all entries for this paper.


Displaying record number 2475

Download this epitope record as JSON.

MAb ID 0.5γ (1C10)
HXB2 Location gp160(308-317) gp160 Epitope Map
Author Location gp120
Epitope SIHIGPGRAF Epitope Alignment
SIHIGPGRAF epitope logo
Subtype B
Ab Type gp120 V3 // V3 glycan (V3g)
Neutralizing P (tier 2)  View neutralization details
Contacts and Features View contacts and features
Species (Isotype) human(IgG1κ)
Patient KTS376
Immunogen HIV-1 infection
Country Japan
Keywords ADCC, antibody binding site, antibody generation, binding affinity, drug resistance, mimics, neutralization

Notes

Showing 3 of 3 notes.

References

Showing 3 of 3 references.

Isolation Paper
Yoshimura2010 Kazuhisa Yoshimura, Shigeyoshi Harada, Junji Shibata, Makiko Hatada, Yuko Yamada, Chihiro Ochiai, Hirokazu Tamamura, and Shuzo Matsushita. Enhanced Exposure of Human Immunodeficiency Virus Type 1 Primary Isolate Neutralization Epitopes through Binding of CD4 Mimetic Compounds. J. Virol., 84(15):7558-7568, Aug 2010. PubMed ID: 20504942. Show all entries for this paper.

Kuwata2016 Takeo Kuwata, Ikumi Enomoto, Masanori Baba, and Shuzo Matsushita. Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies. Antimicrob. Agents Chemother., 60(1):437-450, 2 Nov 2015. PubMed ID: 26525792. Show all entries for this paper.

RamirezValdez2015 Kristel Paola Ramirez Valdez, Takeo Kuwata, Yasuhiro Maruta, Kazuki Tanaka, Muntasir Alam, Kazuhisa Yoshimura, and Shuzo Matsushita. Complementary and Synergistic Activities of Anti-V3, CD4bs and CD4i Antibodies Derived from a Single Individual Can Cover a Wide Range of HIV-1 Strains. Virology, 475:187-203, 15 Jan 2015. PubMed ID: 25486586. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health